Trials / Completed
CompletedNCT01661166
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy )
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- Male
- Age
- 30 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients. Additionally, the correlation between OAB symptoms and urodynamic DO will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fesoterodine | 4 mg |
| DRUG | Placebo oral tablet | Placebo |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2013-04-15
- Completion
- 2013-04-15
- First posted
- 2012-08-09
- Last updated
- 2020-04-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01661166. Inclusion in this directory is not an endorsement.